Treatment of Paget Disease of Bone (Osteitis Deformans): Results of a One-Year Study With Sodium Etidronate

M. Rashid A Khairi, C. Conrad Johnston, Roy D Altman, Henry N. Wellman, Aldo N. Serafini, Roger R. Sankey

Research output: Contribution to journalArticle

Abstract

A double-blind crossover study was performed in which 50 symptomatic patients with Paget disease were treated with sodium etidronate (EHDP) doses of 1, 2.5, 5, 10, or 20 mg/kg or were given placebo. After six months, the patients were reassigned to treatment with placebo or sodium etidronate, 5,10, or 20 mg/kg. Sodium etidronate in dosages of 5,10, or 20 mg/kg/day resulted in significant improvement in levels of serum alkaline phosphatase and urinary hydroxyproline, as well as clinical symptoms and bone scans. Bone scans and urinary determinations showed statistically greater improvement with sodium etidronate 20 mg/kg, in comparison to patients who received sodium etidronate 5 mg/kg for 12 months. After withdrawal of effective therapy, five of nine patients continued to have remission of their symptoms with placebo for an additional six months.

Original languageEnglish (US)
Pages (from-to)562-567
Number of pages6
JournalJAMA - Journal of the American Medical Association
Volume230
Issue number4
DOIs
StatePublished - Oct 28 1974

Fingerprint

Etidronic Acid
Osteitis Deformans
Placebos
Therapeutics
Bone and Bones
Hydroxyproline
Double-Blind Method
Cross-Over Studies
Alkaline Phosphatase
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of Paget Disease of Bone (Osteitis Deformans) : Results of a One-Year Study With Sodium Etidronate. / Khairi, M. Rashid A; Johnston, C. Conrad; Altman, Roy D; Wellman, Henry N.; Serafini, Aldo N.; Sankey, Roger R.

In: JAMA - Journal of the American Medical Association, Vol. 230, No. 4, 28.10.1974, p. 562-567.

Research output: Contribution to journalArticle

Khairi, M. Rashid A ; Johnston, C. Conrad ; Altman, Roy D ; Wellman, Henry N. ; Serafini, Aldo N. ; Sankey, Roger R. / Treatment of Paget Disease of Bone (Osteitis Deformans) : Results of a One-Year Study With Sodium Etidronate. In: JAMA - Journal of the American Medical Association. 1974 ; Vol. 230, No. 4. pp. 562-567.
@article{53a6ce9e9857470bbcac99404b587073,
title = "Treatment of Paget Disease of Bone (Osteitis Deformans): Results of a One-Year Study With Sodium Etidronate",
abstract = "A double-blind crossover study was performed in which 50 symptomatic patients with Paget disease were treated with sodium etidronate (EHDP) doses of 1, 2.5, 5, 10, or 20 mg/kg or were given placebo. After six months, the patients were reassigned to treatment with placebo or sodium etidronate, 5,10, or 20 mg/kg. Sodium etidronate in dosages of 5,10, or 20 mg/kg/day resulted in significant improvement in levels of serum alkaline phosphatase and urinary hydroxyproline, as well as clinical symptoms and bone scans. Bone scans and urinary determinations showed statistically greater improvement with sodium etidronate 20 mg/kg, in comparison to patients who received sodium etidronate 5 mg/kg for 12 months. After withdrawal of effective therapy, five of nine patients continued to have remission of their symptoms with placebo for an additional six months.",
author = "Khairi, {M. Rashid A} and Johnston, {C. Conrad} and Altman, {Roy D} and Wellman, {Henry N.} and Serafini, {Aldo N.} and Sankey, {Roger R.}",
year = "1974",
month = "10",
day = "28",
doi = "10.1001/jama.1974.03240040032027",
language = "English (US)",
volume = "230",
pages = "562--567",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Treatment of Paget Disease of Bone (Osteitis Deformans)

T2 - Results of a One-Year Study With Sodium Etidronate

AU - Khairi, M. Rashid A

AU - Johnston, C. Conrad

AU - Altman, Roy D

AU - Wellman, Henry N.

AU - Serafini, Aldo N.

AU - Sankey, Roger R.

PY - 1974/10/28

Y1 - 1974/10/28

N2 - A double-blind crossover study was performed in which 50 symptomatic patients with Paget disease were treated with sodium etidronate (EHDP) doses of 1, 2.5, 5, 10, or 20 mg/kg or were given placebo. After six months, the patients were reassigned to treatment with placebo or sodium etidronate, 5,10, or 20 mg/kg. Sodium etidronate in dosages of 5,10, or 20 mg/kg/day resulted in significant improvement in levels of serum alkaline phosphatase and urinary hydroxyproline, as well as clinical symptoms and bone scans. Bone scans and urinary determinations showed statistically greater improvement with sodium etidronate 20 mg/kg, in comparison to patients who received sodium etidronate 5 mg/kg for 12 months. After withdrawal of effective therapy, five of nine patients continued to have remission of their symptoms with placebo for an additional six months.

AB - A double-blind crossover study was performed in which 50 symptomatic patients with Paget disease were treated with sodium etidronate (EHDP) doses of 1, 2.5, 5, 10, or 20 mg/kg or were given placebo. After six months, the patients were reassigned to treatment with placebo or sodium etidronate, 5,10, or 20 mg/kg. Sodium etidronate in dosages of 5,10, or 20 mg/kg/day resulted in significant improvement in levels of serum alkaline phosphatase and urinary hydroxyproline, as well as clinical symptoms and bone scans. Bone scans and urinary determinations showed statistically greater improvement with sodium etidronate 20 mg/kg, in comparison to patients who received sodium etidronate 5 mg/kg for 12 months. After withdrawal of effective therapy, five of nine patients continued to have remission of their symptoms with placebo for an additional six months.

UR - http://www.scopus.com/inward/record.url?scp=84942185850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942185850&partnerID=8YFLogxK

U2 - 10.1001/jama.1974.03240040032027

DO - 10.1001/jama.1974.03240040032027

M3 - Article

VL - 230

SP - 562

EP - 567

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 4

ER -